SWS Medical(SH:688410)2026-01-30 07:55Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 140.35 million and 159.49 million CNY, an increase of 69.47 million to 88.61 million CNY compared to the previous year, representing a year-on-year growth of 98% to 125%[3] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 134.37 million and 154.38 million CNY, an increase of 77.19 million to 97.20 million CNY compared to the previous year, reflecting a year-on-year increase of 135% to 170%[3] - The total profit for the previous year was 68.42 million CNY, with a net profit attributable to shareholders of the parent company of 70.89 million CNY[4] - The financial data in this performance forecast has not been audited by an accounting firm[3] - The company has not identified any significant uncertainties that could affect the accuracy of this performance forecast[7] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[8] Business Operations and Growth - The company is a leading domestic blood purification equipment manufacturer, benefiting from technological advantages and strong brand effects, which have driven steady growth in sales revenue[5] - Sales revenue from self-produced blood purification consumables significantly increased during the reporting period[5] - With the increase in production and sales volume, the unit fixed cost of self-produced consumables has decreased, leading to an improvement in gross profit margin and overall profitability[6]